Search

HEPSIN IN THE DIAGNOSIS OF PROSTATE CANCER

Pace G, Pomante R, Vicentini C. Hepsin in the diagnosis of prostate cancer. Minerva Urologica e Nefrologica = The Italian Journal of Urology and Nephrology. 2012 Jun;64(2):143-148.

In the current study we verified whether the expression of hepsin in prostate cancer (PCa) of samples obtained from radical retropubic prostatectomies (RRP) was significantly different from the adjacent normal prostatic tissue. METHODS. We evaluate the expression of hepsin by using immunohistochemistry in PCa tissue in respect to the adjacent normal tissue, of 18 patients who underwent RRP.



Hepsin positive immunoreactivity was estimated on the staining intensity as negative (0), weakly positive (1+), moderately positive (2+), and strongly positive (3+). Hepsin immunoreactivity was detected in 100.0% PCa: 94.4% of cases showed a moderate/strong intensity, 5.6% a weak intensity. The adjacent benign prostatic tissue demonstrated a 83.3% of weak intensity, 11.1% had no reactivity and 5.6% were moderately intense. PCa demonstrated a significant higher (P<0.05) hepsin intensity (2.67) than the adjacent benign tissue (0.94).Hepsin should be regarded as a novel potential immunohistochemical marker for the histopathological diagnosis of PCa.


Read More >

Stay Informed

Sign up to receive the latest news on clinical
trials, publications, investor news and more.

2020 © Navaux, Inc.